Recent Trial Updates: Beam Therapeutics has been a hot topic on X recently, driven by updates on their clinical trials. Posts highlight the company’s progress with BEAM-101 and BEAM-302 for sickle cell disease and alpha-1 antitrypsin deficiency. Investors are keenly awaiting new data expected at the upcoming ASH meeting.
Market Volatility: Discussion on X also reflects concern over recent stock price drops, with some attributing it to broader biotech market volatility. A few users remain optimistic, pointing to the company’s strong cash position and long-term potential. The mix of hope and caution keeps the conversation lively.
Regulatory Risks: Another thread on X focuses on potential regulatory hurdles, including risks from FDA leadership changes and policy shifts. Some express worry about delays in drug reviews, while others see these as temporary setbacks for Beam’s innovative gene-editing platform.
Note: This discussion summary was generated from an AI condensation of post data.
Beam Therapeutics Insider Trading Activity
Beam Therapeutics insiders have traded $BEAM stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $BEAM stock by insiders over the last 6 months:
- LLC FMR has made 0 purchases and 2 sales selling 48,833 shares for an estimated $1,003,913.
- AMY SIMON (Chief Medical Officer) has made 0 purchases and 2 sales selling 1,250 shares for an estimated $23,961.
- CHRISTINE BELLON (Chief Legal Officer) sold 373 shares for an estimated $9,149
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Beam Therapeutics Hedge Fund Activity
We have seen 115 institutional investors add shares of Beam Therapeutics stock to their portfolio, and 128 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 5,041,406 shares (+63.7%) to their portfolio in Q2 2025, for an estimated $85,754,316
- TEMASEK HOLDINGS (PRIVATE) LTD removed 1,812,972 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $30,838,653
- JANUS HENDERSON GROUP PLC removed 1,712,901 shares (-97.7%) from their portfolio in Q2 2025, for an estimated $29,136,446
- VOLORIDGE INVESTMENT MANAGEMENT, LLC added 816,357 shares (+258.8%) to their portfolio in Q2 2025, for an estimated $13,886,232
- GOLDMAN SACHS GROUP INC added 605,961 shares (+89.5%) to their portfolio in Q2 2025, for an estimated $10,307,396
- QUBE RESEARCH & TECHNOLOGIES LTD added 593,815 shares (+inf%) to their portfolio in Q2 2025, for an estimated $10,100,793
- PRICE T ROWE ASSOCIATES INC /MD/ removed 583,825 shares (-19.3%) from their portfolio in Q2 2025, for an estimated $9,930,863
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Beam Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $BEAM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/10/2025
To track analyst ratings and price targets for Beam Therapeutics, check out Quiver Quantitative's $BEAM forecast page.
Beam Therapeutics Price Targets
Multiple analysts have issued price targets for $BEAM recently. We have seen 2 analysts offer price targets for $BEAM in the last 6 months, with a median target of $50.5.
Here are some recent targets:
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $80.0 on 10/10/2025
- Gena Wang from Barclays set a target price of $21.0 on 08/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
